Clinical and biological characteristics of patients with CML according to the severity categorization of SARS-CoV-2 infection
| Category of SARS-CoV-2 infection . | No. of patients . | CML phase at diagnosis of SARS-CoV-2 infection . | Age range/average age, y . | No. of patients with noninfectious comorbidities . | Sex . | No. of patients with/without CHR . | No. of patients from the relative risk group according to Sokal score . | Range and median value of the period CML diagnosis → COVID-19 diagnosis, mo . | No. of patients with viral pneumonia proved by X-ray examination . | No. of hospitalized patients due to SARS-CoV-2 infection . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chronic . | Accelerated . | Acute . | Males . | Females . | Achieved . | Not achieved . | Low . | Intermediate . | High . | |||||||
| Mild | 5 (25%) | 5 (25%) | — | — | 38-62/50.2 | — | 3 (15%) | 2 (10%) | 5 (25%) | — | 4 (20%) | — | 1 (5 %) | 63.5-214/119.1 | — | — |
| Moderate | 10 (50%) | 10 (50%) | — | — | 39-65/52.0 | — | 6 (30%) | 4 (20%) | 10 (50%) | — | 5 (25%) | 5 (25%) | — | 30-175.5/74.9 | 4 (20%) | 7 (35%) |
| Severe | 5 (25%) | 3 (15%) | 1 (5%) | 1 (5%) | 38-74/57.0 | 5 (100%) | 3 (15%) | 2 (10%) | 3 (15%) | 2 (10%) | 1 (5%) | 3 (15%) | 1 (5 %) | 98.5-155/130.9 | 5 (25%) | 5 (25%) |
| Total | 20 (100%) | 18 (90%) | 1 (5%) | 1 (5%) | 38-74/53.0 | 5 (25%) | 4 (100%) | 8 (40%) | 18 (90%) | 2 (10%) | 10 (50%) | 8 (40%) | 2 (10%) | 30-214/108.3 | 9 (45%) | 12 (60%) |
| Category of SARS-CoV-2 infection . | No. of patients . | CML phase at diagnosis of SARS-CoV-2 infection . | Age range/average age, y . | No. of patients with noninfectious comorbidities . | Sex . | No. of patients with/without CHR . | No. of patients from the relative risk group according to Sokal score . | Range and median value of the period CML diagnosis → COVID-19 diagnosis, mo . | No. of patients with viral pneumonia proved by X-ray examination . | No. of hospitalized patients due to SARS-CoV-2 infection . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chronic . | Accelerated . | Acute . | Males . | Females . | Achieved . | Not achieved . | Low . | Intermediate . | High . | |||||||
| Mild | 5 (25%) | 5 (25%) | — | — | 38-62/50.2 | — | 3 (15%) | 2 (10%) | 5 (25%) | — | 4 (20%) | — | 1 (5 %) | 63.5-214/119.1 | — | — |
| Moderate | 10 (50%) | 10 (50%) | — | — | 39-65/52.0 | — | 6 (30%) | 4 (20%) | 10 (50%) | — | 5 (25%) | 5 (25%) | — | 30-175.5/74.9 | 4 (20%) | 7 (35%) |
| Severe | 5 (25%) | 3 (15%) | 1 (5%) | 1 (5%) | 38-74/57.0 | 5 (100%) | 3 (15%) | 2 (10%) | 3 (15%) | 2 (10%) | 1 (5%) | 3 (15%) | 1 (5 %) | 98.5-155/130.9 | 5 (25%) | 5 (25%) |
| Total | 20 (100%) | 18 (90%) | 1 (5%) | 1 (5%) | 38-74/53.0 | 5 (25%) | 4 (100%) | 8 (40%) | 18 (90%) | 2 (10%) | 10 (50%) | 8 (40%) | 2 (10%) | 30-214/108.3 | 9 (45%) | 12 (60%) |